News

Stephen Hazelton, the founder of the credit document analytics group Street Diligence, characterised the toy retailer’s capital structure as “extremely complicated”. Guarantees between its US and foreign operations have muddied the water of who has first claim on any eventual payments Toys R Us is...

Street Diligence identifies four key covenant trends   Equity Cure: An equity cure is an infusion of cash by a private equity sponsor, mainly due to a breach of a financial covenant. It allows the sponsor to more effectively manage extraction of cash from the balance sheet...

Private equity firms have slowly started to push loans that have restrictions on which investors the debt can be sold to, limiting the amount of bargaining that can take place. Stephen Hazelton, Founder and CEO of Street Diligence, explores with Finance Monthly the long-term impact eroding...

APPEARED IN HEDGE WEEK JUNE, 2017. Data analytics platform Street Diligence has launched Bank Loan and High Yield Screener, which is designed to provide comprehensive analysis and instant comparability of covenant data. The platform, the first and only credit focused analytics platform built for buy and sell-side...

Street Diligence, the leading provider of fixed income data and due diligence walked away with the runner-up prize in The Best Research Category from the Benzinga Global Fintech Awards in New York City May 11.   “The entire Benzinga team wants to congratulate Street Diligence, on its...

APPEARED IN THE STREET JUNE, 2016   When it comes to fixed-income investments, the devil is in the details, especially when a credit event such as a default is approaching. Because the specter of default is omnipresent in the high-yield bond market, investors who trade these securities scour...

APPEARED IN MARKETWATCH  JULY, 2016. BY STREET DILIGENCE.  With its stock dropping below $20 from a peak of $263.81, the bleak outlook for Valeant Pharmaceuticals International Inc. is largely priced into its stock, but its bonds have yet to catch up. Valeant VRX, +1.10%  bonds are currently...